Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 18.
doi: 10.1097/RHU.0000000000002281. Online ahead of print.

Real-world Outcomes and Tolerability of Nintedanib in Patients With Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease: A Retrospective Study From a Single Center in a Middle Eastern Population

Rajaie Namas  1 , Sarah Al Qassimi  1 , Mohamed Elarabi  1 , Saniya Khan  2 , Ahlam Almarzooqi  3 , Asia Mubashir  1 , Waleed Hafiz  4 , Jeffery Chapman  2
Affiliations

Real-world Outcomes and Tolerability of Nintedanib in Patients With Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease: A Retrospective Study From a Single Center in a Middle Eastern Population

Rajaie Namas et al. J Clin Rheumatol. .

Abstract

Background: Nintedanib, a tyrosine kinase inhibitor with antifibrotic properties, has been shown to significantly slow the progression of pulmonary fibrosis. The aim of this study is to assess the clinical characteristics, longitudinal pulmonary function tests, serial high-resolution computed tomography (HRCT) findings, and the efficacy, tolerability, and outcomes of nintedanib treatment in patients with systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) within a Middle Eastern population.

Patients and methods: This is a cohort study conducted between May 2015 and March 2024, all patients with SARD-ILD treated with nintedanib were analyzed. Demographic and clinical data were collected before the initiation of nintedanib. Serial changes in percentage predicted forced vital capacity (ppFVC) and percentage predicted diffusing capacity for carbon monoxide (ppDLCO), as well as HRCT findings, were recorded at 6, 12, and 24 months posttreatment initiation. Adverse events of nintedanib were documented. Descriptive statistics were employed for data analysis.

Results: A total of 47 patients with SARD-ILD received nintedanib. The most common diagnoses were systemic sclerosis (36.2%) and rheumatoid arthritis (17%). Over 24 months, patients showed stable or slightly improved ppFVC and ppDLCO values, and 89% had stable ILD on HRCT. Gastrointestinal adverse events were reported in 27.7% of patients. Five patients (10.6%) underwent lung transplantation, with an average time of 3.2 ± 2.2 years from treatment initiation to transplantation.

Conclusion: Our findings indicate that nintedanib is well-tolerated, with no new safety concerns identified. In addition, we observed clinically meaningful improvements in pulmonary function tests by 6 months, which were sustained through 24 months.

Keywords: interstitial lung disease; nintedanib; systemic rheumatic autoimmune disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372–378.
    1. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380:689–698.
    1. Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med. 2019;200:1258–1266.
    1. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. 2002;22:S151–S165.
    1. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.

LinkOut - more resources